advertisement
Editors Selection IGR 10-2
Medical Treatment: Beta-2 adrenergic receptor and IOP reduction
Comment by Rand Allingham on:
21744 Intraocular pressure response to topical β-blockers associated with an ADRB2 single-nucleotide polymorphism, McCarty CA; Burmester JK; Mukesh BN et al., Archives of Ophthalmology, 2008; 126: 959-963
Pharmacogenomics examines the role of genetic variation in the efficacy and toxicity of drug therapy which allows physicians to utilize the patient's genetic information to optimize that patient's medical care. McCarty et al. (1175) examined the relationship between genetic variants in beta(1)-, beta(2)-, and beta(3)-adrenergic receptors and CYP2D6 upon IOP response to topically applied beta-blockers. The Marshfield Clinic Personalized Medicine Research Project dataset containing medical information and DNA from over 19,000 subjects was used. An association between one variant in the beta2-adrenergic receptor (Gln27Glu) and IOP response was found. Individuals with this variant had a two-fold increased likelihood (p = 0.05) of a 20% IOP reduction with treatment. No association was found between genetic variants tested in the other candidate genes. Although this result may not support the use of this test in the clinical setting, perhaps the most important aspect of this study is the utilization of a powerful population-based genomic datasets to answer these important questions. As the number of treatment options expand in number and complexity, patient care guided by pharmacogenomic evidence will play an increasingly important role in patient care. Tailoring medical treatment to the individual patient will improve treatment efficacy and reduce potentially costly adverse effects.
Comments
The comment section on the IGR website is restricted to WGA#One members only. Please log-in through your WGA#One account to continue.Log-in through WGA#One
